Pradigastat

Overview

Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC 50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP , OATP1B1, OATP1B3 and OAT3 activities with IC 50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Signaling Pathways > Acyltransferase | Products > Signaling Pathways > BCRP | Products > Signaling Pathways > OAT

Product Information

• Catalog No.: HY-16278
• CAS No.: 956136-95-1
• Molecular Formula: C25H24F3N3O2
• Molecular Weight: 455.47
• Purity: 99.88%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (5.49 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source